Vertex Pharmaceuticals (VRTX) Inventory Average (2011 - 2026)

Vertex Pharmaceuticals' Inventory Average history runs 16 years deep, the most recent figure standing at $1.7 billion for Q1 2026.

• On a quarterly basis, Inventory Average rose 34.63% year-over-year to $1.7 billion in Q1 2026; TTM through Mar 2026 was $1.7 billion, a 34.63% increase from a year earlier, with the FY2025 full-year figure at $1.4 billion, up 48.76% from the prior year.
• Inventory Average improved to $1.7 billion in Q1 2026 per VRTX's latest filing, from $1.7 billion in the prior quarter.
• Across five years, Inventory Average topped out at $1.7 billion in Q1 2026 and bottomed at $346.0 million in Q1 2022.
• The 5-year median for Inventory Average is $775.9 million (2024), against an average of $903.9 million.
• Across the five-year window, Inventory Average rose 13.88% in 2022 and soared 70.95% in 2023, its largest moves.
• Year by year, Inventory Average stood at $424.4 million in 2022, then soared by 68.18% to $713.8 million in 2023, then soared by 60.08% to $1.1 billion in 2024, then surged by 45.0% to $1.7 billion in 2025, then gained by 4.22% to $1.7 billion in 2026.
• Per Business Quant, the three latest VRTX Inventory Average figures stand at $1.7 billion (Q1 2026), $1.7 billion (Q4 2025), and $1.6 billion (Q3 2025).